Fulcrum Therapeutics, Inc. (FULC) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

Earnings Reports

• Fulcrum Therapeutics (FULC) Q1 2026: $333M Cash Runway Extends to 2029 as Sickle Cell Data Drives Next-Phase Strategy
  April 27, 2026
• Fulcrum Therapeutics (FULC) Q3 2025: Cash Runway Extends Into 2028 as Sickle Cell Data Drives Clinical Momentum
  October 29, 2025
• Fulcrum Therapeutics (FULC) Q1 2025: R&D Spend Falls 32% as Pioneer Trial Hits 16-Patient Enrollment Milestone
  July 04, 2025

Browse all companies